最新研究显示,截至2026年8月,大不列颠已有8.5%的家庭中至少有一名成员正在服用GLP-1类减肥药物1。这一比例意味着约有260万成年人成为该类药物用户,相比同年2月增加了约70万人1。Worldpanel by Numerator高级顾问Nishita Pattni指出,在2026年2月至8月这短短六个月内,用户数量的增长幅度几乎等同于上一整年的增长总量1。
口服剂型的获批是推动使用率激增的关键因素之一。Wegovy等减肥药片于2026年6月在英国获得批准,打破了此前患者仅能使用注射剂型的限制1。目前,药片形式已占所有GLP-1使用者的11.2%以上1。与此同时,男性用户群体显著扩大,其占比从2月的23%上升至32%,人数接近翻倍,达到83万1。
随着减肥药的普及,相关家庭的消费习惯发生了明显变化。数据显示,在使用药物的一年内,拥有GLP-1使用者的家庭在食品杂货上的支出比预期减少了10亿英镑1。具体品类方面,酒精和薯片的支出分别下降了15%以上,而冷冻即食餐的销量则增长了30%1。专家预测,到2027年,GLP-1类药物的使用将超过英国家庭总数的10%,这将迫使零售商和制造商调整策略以适应新的消费趋势1。
A recent study reveals that weight-loss medications have rapidly become a household staple across Great Britain. As of August 2026, at least one person is using GLP-1 class drugs in 8.5% of households 1. The total number of adult users reached approximately 2.6 million in August, marking an increase of roughly 700,000 people since February of the same year 1. This surge has had immediate economic impacts on retail, with grocery spending in households containing a GLP-1 user falling by £1 billion below expected levels over the course of a year 1. Specifically, expenditure on alcohol and crisps dropped by more than 15%, while sales of frozen ready meals rose by 30% 1.
The rapid adoption is driven partly by regulatory changes and shifting demographics. In June, oral pill formulations such as Wegovy received approval in the UK, ending the previous monopoly of injectable options 1. Consequently, pills now account for over 11.2% of all GLP-1 users 1. The uptake among men has also accelerated significantly; male usage jumped from 23% to 32% between February and August, bringing the number of male users close to doubling at 830,000 1. Nishita Pattni, a senior consultant at Worldpanel by Numerator, highlighted the unprecedented speed of this growth: "In just six months from February to August 2026, the increase in users was almost equivalent to the growth of the entire previous year." 1 Looking ahead, projections indicate that GLP-1 usage will surpass penetration in 10% of British homes by 2027 1.
评论
还没有评论,欢迎留下第一条。